论文部分内容阅读
目的:分析新疆维吾尔族妊娠期高血压疾病血清中MMP-9、TIMP-1的表达水平及其与妊娠期高血压疾病的相关性,为临床提前干预治疗工作提供理论依据。方法:采用ELISA法检测60例妊娠期高血压疾病患者(其中轻度组和重度组各30例)及30例健康孕妇血清中MMP-9和TIMP-I水平。结果:妊娠期高血压疾病重度组患者血清MMP-9水平显著低于正常对照组及轻度组(P<0.05)差异有显著性;而妊娠期高血压轻度组与正常组之间无显著差异性(P>0.05),但在重度组中MMP-9的浓度较其他两组明显减低;TIMP-I妊娠期高血压疾病重度组、轻度组及正常对照组血清中各组相互比较均表达差异无显著性(P>0.05),无统计学意义,且TIMP-1在三组中的浓度值变化不大,可见虽然重度妊娠期高血压疾病患者血清中MMP-9表达下降,而它的特异性抑制物TIMP-1却无相应的变化,这导致两者之间的平衡状态发生改变,MMP-9/TIMP-l比值下降。结论:血清中MMP-9及TIMP-1表达异常可能与妊娠高血压综合征的发病有密切的关系。MMP-9、TIMP-1有望成为妊娠期高血压疾病进行提前干预治疗的手段。
Objective: To analyze the expression of MMP-9 and TIMP-1 in the serum of gestational hypertensive disorders in Uygur in Xinjiang and its relationship with hypertensive disorder complicating pregnancy, and to provide a theoretical basis for clinical intervention. Methods: Serum levels of MMP-9 and TIMP-1 in 60 patients with gestational hypertension (30 in mild and severe group) and 30 healthy pregnant women were detected by ELISA. Results: The serum level of MMP-9 in patients with severe gestational hypertension group was significantly lower than that in the normal control group and mild group (P <0.05), while there was no significant difference between the moderate and severe hypertensive disorders group (P> 0.05), but in the severe group, the concentration of MMP-9 was significantly lower than the other two groups; TIMP-I gestational hypertensive disorder in severe group, mild group and normal control group serum were compared with each other There was no significant difference between the two groups (P> 0.05), but there was no significant difference between the three groups (P> 0.05). Although the expression of MMP-9 in serum of patients with severe gestational hypertension decreased, The specific inhibitor TIMP-1 did not change accordingly, which led to a change in the balance between the two, MMP-9 / TIMP-1 ratio decreased. Conclusion: The abnormal expression of MMP-9 and TIMP-1 in serum may be closely related to the pathogenesis of pregnancy-induced hypertension syndrome. MMP-9, TIMP-1 is expected to become a means of early intervention treatment of hypertensive disorders of pregnancy.